Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Large Growth in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 7,780,000 shares, a growth of 94.5% from the December 31st total of 4,000,000 shares. Currently, 4.2% of the shares of the company are sold short. Based on an average daily trading volume, of 100,730,000 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research note on Saturday, January 25th. They set a "hold" rating for the company.

Tonix Pharmaceuticals Price Performance

Shares of Tonix Pharmaceuticals stock traded up $0.05 on Friday, hitting $0.43. The company's stock had a trading volume of 71,543,744 shares, compared to its average volume of 97,665,104. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. Tonix Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $12.48. The firm has a fifty day moving average price of $0.30 and a 200-day moving average price of $0.28. The company has a market capitalization of $80.01 million, a price-to-earnings ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. As a group, sell-side analysts anticipate that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. Institutional investors own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.